ENTB Entest BioMedical Inc

[chuck44l]

Entest BioMedical Inc. (OTCBB: ENTB) The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), cancer immuno-therapies, testing procedures for diabetes and stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).

Currently, Entest is focused on research and development in areas of COPD and Immuno-Therapeutic Cancer Vaccines. The Company sees applications for its patent pending technologies in both human and animal venues.

Immuno-therapeutic treatment of cancer – The patent pending Entest application involves perfecting the use of cell lines for sustained release of immunologically relevant cytokines for maximum anti-tumor immune responses in treating cancer. The treatment process itself will utilize an implantable encapsulation device as the vaccine delivery system and the initial focus will be treatment of cancer in canines. This canine cancer treatment may also provide clinical support for expansion into human cancer treatment.

Chronic Obstructive Pulmonary Disease –There is currently no cure for COPD and therapy is limited to management of the condition and its symptoms. Over the next 5 years, it is estimated that over $170 billion will be spent on treating COPD in the United States. Entest believes its COPD treatment, which utilizes patent pending adult stem cell therapy coupled with photoceutical device enhancement, has the potential to reverse COPD related lung damage as well as alleviate symptoms.

Entest BioMedical was founded for the purpose of providing excellence in biotechnology research (including adult stem cell regenerative treatment). Our objectives go beyond developing single products and procedures. Our mission is to discover and develop new procedures, treatments and medical devices that improve the quality of life. Our efforts revolve around a business focus of developing leading research and technology. Ongoing R&D is paramount to us in developing products and procedures with purpose, products and services that serve the present and help shape the future.

[chuck44l]

g. Entest BioMedical Files Patent Application for Selective Targeting of Stem
Cells to Lung Using Photoceutical Devices -- New Technology to Increase
Efficacy of Adult Stem Cells in COPD Treatment ( November 4, 2009)

Entest BioMedical (OTCBB: ENTB) announced today it has filed a second patent
application in the area of Chronic Obstructive Pulmonary Disease (COPD). This
new patent application builds upon the Company’s previously filed COPD patent
application and involves the use of photoceutical devices to target stem cells
toward areas impacted by COPD in the lungs.

Steve Josephs, PhD, a Scientific Advisor to the Company stated “that by using
photoceutical devices in treating COPD, it is believed stem cells can be focused
on areas of the lungs where there is damage. Furthermore, being able to target
specific areas and draw stem cells to those areas should produce greater
efficacy in patient treatment outcomes. ”

David Koos, Chairman and CEO of Entest stated, “This new patent application
we filed covers methods of enhancing our previously disclosed adult stem cell
technologies in the treatment of COPD. It is our belief the use of photoceuticals
devices coupled with adult stem cell therapy is a treatment model completely
new and unique to addressing this terrible disease.”

Entest’s treatment approach for COPD is based on the development of easy-toimplement
therapies involving the use of stem cells, and other cells found in the
fat tissue of the patient. By incorporating photoceutical devices currently in use
for other clinical treatments, this invention discloses methods of increasing the
rate of cell homing, retention, and growth factor production in the lung.

h. Entest Biomedical Applying for National Cancer Institute Contract for the
development of Anti-Cancer Immunotherapy Drug -- First stage of contract
to be $200,000 (November 10, 2009)

Entest BioMedical Inc. (OTC BB: ENTB) is applying for a National Cancer
Institute (NCI) Small Business Innovative Research (SBIR) Contract for the
development of Anti-Cancer Agents. This contract, if awarded to Entest, will
have a value of $200,000 for the initial development of an immuno-therapeutic
cancer drug.

Entest recently filed a patent application in conjunction with Therinject LLC for
this immuno-therapeutic drug. NCI’s, should it award the contract to Entest, will
work with the Company to move the drug application through clinical trials and
approvals, with the end result being commercialization of the technology. The
Company believes NCI’s goal is to address a niche segment of tumor treatment,
which its patent pending technology addresses.

Entest’s method involves perfecting the use of an existing anti-tumor response
drug. This drug is then administered through a new delivery method,
incorporating the drug as an injectable within microspheres (small beads)
allowing it to be placed directly within the tumor. Previous approaches involve
oral dosage, causing the drug to circulate through the entire body, producing
mixed results. It is Entest’s hope that this approach will generate anti-tumor
immune responses and result in an effective cancer treatment.

The short-term goal of this Phase I Contract is to investigate this new anti-tumor
drug and this alternative delivery method in order to establish a rationale with the
National Cancer Institute (NCI) for continued development of the drug and the
potential for filing an Investigational New Drug Application (IND). Later, if
successful, Entest Biomedical plans to file a Phase II clinical trial grant
application, and to take the drug to market.

Principal Investigator Dr. Steven F. Josephs says, “This new approach to an
existing drug, we hope, will eliminate previous side-effects and result in a
groundbreaking treatment that obviates or reduces the need for chemotherapy or
radiation treatments.”

I. Entest BioMedical, Inc. Discusses How Therapies in Development May
Yield Lucrative Revenue Streams for the Company -Current focus on COPD
and Immuno-Therapeutic Cancer Treatment (November 10, 2009)

Entest BioMedical, Inc. (OTCBB: ENTB) discussed its current therapies in
development in the areas of immuno-therapeutic treatment of cancer and
Chronic Obstructive Pulmonary Disease (COPD) and their potential to generate
significant revenue for the Company.

a. Immuno-therapeutic treatment of cancer – The patent pending Entest
application involves perfecting the use of cell lines for sustained release of
immunologically relevant cytokines for maximum anti-tumor immune
responses in treating cancer. The treatment process itself will utilize an
implantable encapsulation device as the vaccine delivery system and the
initial focus will be treatment of cancer in canines. The Company’s initial
goal is to treat 2,000 dogs at $3,000 per dog (yielding $6,000,000 in
revenue) and believes revenue could begin to be generated within the next
9 months. This canine cancer treatment may also provide clinical support
for expansion into human cancer treatment.

b. Entest has applied for a contract with the National Cancer Institute (NCI)
for the initial development of an immuno-therapeutic cancer drug. This
contract, if awarded to Entest, will have a value of $200,000 and will cover
Phase I clinical evaluation. If the drug demonstrates reasonable efficacy,
NCI may coordinate and fund further development through Phases II and
III, with the ultimate goal being commercialization of the drug in partnership
with NCI.

c. COPD –There is currently no cure for COPD and therapy is limited to
management of the condition and its symptoms. Over the next 5 years, it is
estimated that over $170 billion will be spent on treating COPD in the
United States. Entest believes its COPD treatment, which utilizes patent
pending adult stem cell therapy coupled with photoceutical device
enhancement, has the potential to reverse COPD related lung damage as
well as alleviate symptoms. The Company foresees substantial revenue in
treating COPD and is currently in discussions with several entities
regarding possible joint ventures involving the Company’s developing
patent pending treatment.

d. Entest anticipates funding a significant amount of its research development
costs by obtaining grant funding. The Company is in the process of
applying for $3 million of federal grant funding for both COPD treatment
and immuno-therapeutic treatment of cancer.

[chuck44l]

Entest BioMedical Inc. has signed a letter of intent to acquire Therinject LLC.
Therinject LLC is involved with Cancer Research, marker testing / development
and “bead” formation used in vaccine development. Company Chairman David
Koos noted “Entest BioMedical has already established a joint venture with
Therinject LLC. I believe this is an obvious natural fit and removes any potential
conflicts between each company’s goals.”


Therinject’s Managing Principal, Steven Josephs, PhD stated “I have been
involved with new develops taking place at Entest for some time. I’m excited that
Therinject will become an Entest company. I believe we are doing some
extremely important work in cancer treatment, COPD and potentially Multiple
Sclerosis. With the linking of these companies together, we should get further in
our research at a much faster pace.”


Once a definitive agreement is in place, Therinject LLC will become a wholly
owned subsidiary of Entest BioMedical Inc. This transaction is subject to
reaching final agreement on terms and conditions.


e. Entest BioMedical, Inc. to Aggressively Pursue Private and Public Grants to
Fund Research for Development of Stem Cell Treatment of Chronic
Obstructive Pulmonary Disease (COPD) -- Initiates Activities by Retaining
Grant Development Firm to Source Research Funding / COPD Impacts Over
24 million Americans, 4th Leading Cause of Death in United States (October
14, 2009)


Entest BioMedical has retained a private grant research and development firm to aggressively pursue both private and public sector grant funding of research in the area of Stem Cell Therapy for Chronic Obstructive Pulmonary Disease (COPD) conducted by Entest BioMedical, Inc.


Entest BioMedical believes its research in COPD could offer dramatic
improvement and new hope for patients suffering from this debilitating condition.
Utilizing a firm that specializes in sourcing private and public sector grant funding
will allow the Company to move its research forward much faster, so that it may
make stem cell treatment for COPD available to physicians and patients as
quickly as possible. More than 12 million people are currently diagnosed with
COPD. An additional 12 million likely have the disease but are not yet
diagnosed.”


Currently, Entest is preparing to undertake small sample testing of its patent
pending stem cell technology for COPD. Grant funding from private and public
sources will allow the Company to move rapidly towards filing an Investigational
New Drug (IND) application with the FDA on this novel treatment. Once the IND
has been approved, the Company anticipates moving forward into large scale
clinical trials.


f. Entest BioMedical Signs LOI with Quantum Advisors to Coordinate
Development of COPD Stem Cell Therapy -- $832 Billion in COPD Medical
Related Costs Projected over next 20 years in United States means
potentially huge market for Entest’s Stem Cell therapy (November 3, 2004)


Entest BioMedical Inc. announced today that it has signed a letter of intent with
Quantum Advisors, a San Diego based biotechnology consulting firm, to assist
Entest with the development of its Stem Cell Therapeutic Treatment for Chronic
Obstructive Pulmonary Disease (COPD).


An Entest spokesperson stated that Quantum’s role in this research will be to
work with Company scientists, Contract Research Organizations (CROs) and
Regulatory authorities in moving forward with clinical testing of Entest’s patent
pending technology. Quantum will also be involved with assisting the Company
with its Investigational New Drug (IND) submission to the FDA.


David Koos, Entest’s Chairman & CEO said “Our relationship with Quantum is
extremely valuable to our Company. Not only will they be working with us to
develop our stem cell therapy for COPD, they will help identify appropriate Joint
Venture candidates for commercialization of this technology. What this means to
COPD patients -- we are going to do all that is possible to bring this treatment for
COPD to doctors and hospitals at the earliest possible date.”

[chuck44l]

• Entest BioMedical, Inc. files Stem Cell Therapy patent application for
treatment of COPD -- Adipose Stem Cells to be used (August 19, 2009)

• Entest BioMedical Finalizes New Immuno-therapeutic Cancer Vaccine
Joint Venture withTherinject -- Initial Market to be Veterinary Medicine --
$60 Million potential over 5 years (August 26, 2009)

• Entest BioMedical Inc. Comments on New Opportunities for the Company
-- (September 1, 2009)

• Bio-Matrix Scientific Group’s Subsidiary Applies for Phase II Grant from
National Cancer Institute for the Development of Immuno-Therapeutic
Cancer Vaccine

• Entest BioMedical Announces Intent to Acquire Cancer Research
Company Therinject LLC -- Therinject to bring its cancer research,
intellectual property and former National Cancer Institute Researcher
under the Entest BioMedical Umbrella (October 7, 2009)

• Entest BioMedical, Inc. to Aggressively Pursue Private and Public Grants
to Fund Research for Development of Stem Cell Treatment of Chronic
Obstructive Pulmonary Disease (COPD) -- Initiates Activities by Retaining
Grant Development Firm to Source Research Funding / COPD Impacts
Over 24 million Americans, 4th Leading Cause of Death in United States
(October 14, 2009)

• Entest BioMedical Signs LOI with Quantum Advisors to Coordinate
Development of COPD Stem Cell Therapy -- $832 Billion in COPD
Medical Related Costs Projected over next 20 years in United States
means potentially huge market for Entest’s Stem Cell therapy (November
3, 2004)

• Stem Cells to Lung Using Photoceutical Devices -- New Technology to
Increase Efficacy of Adult Stem Cells in COPD Treatment ( November 4,
2009)

• Entest Biomedical Applies for National Cancer Institute Contract for the
development of Anti-Cancer Immunotherapy Drug -- First stage of contract
to be $200,000 (November 10, 2009)

• Entest BioMedical, Inc. Discusses How Therapies in Development May
Yield Lucrative Revenue Streams for the Company -Current focus on
COPD and Immuno-Therapeutic Cancer Treatment (November 10, 2009)


1.) Discussion and Description of Company Milestones:


a. Entest BioMedical, Inc. files Stem Cell Therapy patent application for
treatment of COPD -- Adipose Stem Cells to be used (August 19, 2009)


Chronic Obstructive Pulmonary Disease (COPD) is a major health disorder that
appears to be treatable through adipose derived stem cell therapy. COPD is a
group of lung inflammatory diseases which includes both emphysema and
chronic obstructive bronchitis affecting more than 5 million Americans each year.
It is the fourth leading cause of death in America, impacting more than 5 million
Americans, resulting in more than 120,000 deaths in the USA per a year.
Currently, this disease is treated in similar fashion to asthma, utilizing inhalers
and /or oxygen therapy. These methods are not solutions to the disease but
merely provide the patient with greater level of comfort.


Steven Josephs, PhD. noted “The approach is intended at the very least to
alleviate the chronic inflammation in COPD. This is done by using agents known
to coax adult stem cells that are delivered to the diseased lung tissue (blood
monocyte cells) to release cytokines (biologically active molecules) which in
addition to the anti-inflammatory effects may actually promote the regeneration of
functional lung tissue.”


The goal of Entest BioMedical, Inc. is to develop a stem cell therapy that
reverses the effects of COPD on the respiratory system. The Company is
working with Dr. Feng Lin, its Scientific Director and Steven Josephs, PhD in
developing this stem cell treatment.



b. Entest BioMedical Finalizes New Immuno-therapeutic Cancer Vaccine Joint
Venture withTherinject -- Initial Market to be Veterinary Medicine -- $60
Million potential over 5 years (August 26, 2009)


Entest BioMedical Inc. finalized a definitive agreement with Therinject LLC for the
development of a new immuno-therapeutic cancer vaccine. Therinject LLC is
engaged in the development of cancer treatments utilizing immunology based
approaches.


Cancer is the #1 cause of death among dogs. It’s estimated that 1 out of every 3
dogs will get cancer. It is anticipated this immuno-therapeutic cancer vaccine
could have an efficacy rate of as high as 60% where 15% to 20% is the current
cure rate. It is believed that during the first year this immuno-therapeutic vaccine
is available we will treat roughly 2,000 animals resulting in $3,000 revenue per
animal or $6 million in first year revenue from veterinary medical applications.


The Company anticipates a market niche over the subsequent 5 years of 40,000
animals being treated. This is before we expand to human clinical trials.”
Therinject’s Chief Scientific Officer, Steven Josephs, Ph.D. said that “for many
cancers, efficacy rates should be much higher than currently available therapies.
Immuno-therapy stimulates the body’s own immune system to engage in the
treatment process. The development of an anti-cancer immune response would
be very effective in dealing with metastatic tumors especially in cases where
surgery would no longer be feasible.”


Additionally, Therinject will work with Entest BioMedical’s team to develop
intellectual property in this area of cancer treatment, which is anticipated to result
in patents being applied for by Entest BioMedical Inc.


Bio-Matrix Scientific Group’s Subsidiary Applies for Phase II Grant from
National Cancer Institute for the Development of Immuno-Therapeutic
Cancer Vaccine -- Entest BioMedical Inc. Sees Therapeutic Vaccine
Impacting $72 Billion A Year Cancer Treatment Industry in United States
(October 7, 2009)


Entest Biomedical, Inc. announced today that it has applied for an
Exploratory/Development Phase II grant from the National Cancer Institute (NCI).
David Koos, Chairman and CEO of Bio-Matrix Scientific Group and its majority
owned subsidiary, Entest Biomedical, Inc. says, “Our goal with this research is to
test a viable and groundbreaking cancer treatment, first in the veterinary
oncology market and then, if successful, to move on to human clinical trials.”


The Entest application involves perfecting the use of cell lines for sustained release of
immunologically relevant cytokines for maximum anti-tumor immune responses in
treating cancer. The treatment process will utilize an implantable chamber device as the
vaccine delivery system. This process has already been demonstrated effective on
treating tumors in both rodent and canine models. The grant application has already
been assigned to a Scientific Review Group for scientific merit evaluation.


Principal Investigator Dr. Steven F. Josephs says, “If successful, this approach reduces
the need for chemotherapy or radiation treatments since the enhanced immune system
is engaged in eliminating cancerous tissue on its own. In doing this, we are allowing the
subject to recover without the damage that generally occurs with more traditional cancer
treatments.” Josephs continues, “This work, if successful, should result in a
groundbreaking discovery for cancer therapy.”


Once efficacy has been achieved in this study, the Company plans to develop a
commercially viable treatment for canines, which could impact approximately 36 million
dogs in United States that suffer from cancer, according to the Morris Animal Foundation
and the American Veterinary Medical Association.


Additionally, Entest Biomedical, Inc. anticipates this treatment option could have marked
effects on the human oncology market, which the National Cancer Institute (NCI)
estimated at more than $72 billion in 2004. In 2009, NCI’s SEER Cancer Statistics
Review estimates that more than 1.4 million men and women in United States will be
diagnosed with cancer. .


c. Entest BioMedical Inc. Comments on New Opportunities for the Company
(September 1, 2009)


Entest BioMedical commented on the Company’s new opportunities in stem cell
research, cancer treatment and intellectual property. Mr. Koos noted “In the last
3 months we have made substantial progress in areas we believe will be
accretive for our shareholders. It is my belief that our business model is far more
balanced and progressive today than we have previously been. The new
opportunities on the table for us now should diversify our revenue model and
complement each other as the Company grows. We see Entest BioMedical
(OTCBB: ENTB) leading the way in expanding the Company’s core business.”


Recent Developments include:


Entering into discussions and due diligence process regarding a potential
mutually beneficial business arrangement with a biotech company that is in FDA
Fast Track for Phase 3 Clinical Trials on the development of a cancer treatment.



The execution of an agreement with Therinject LLC regarding, among other
matters, the development and marketing of a therapeutic cancer vaccine for initial use in veterinary applications as well as the Company’s entry into Tumor Cell Banking



The filing of a patent application by Entest Biomedical for the use of adipose (fat)
derived stem cells in the treatment of Chronic Obstructive Pulmonary Disease
(COPD).


Entering into discussions with a biomedical manufacturer to jointly produce a
medical device used in diabetes and cancer research.


d. Entest BioMedical Announces Intent to Acquire Cancer Research Company
Therinject LLC -- Therinject to bring its cancer research, intellectual
property and former National Cancer Institute Researcher under the Entest
BioMedical Umbrella (October 7, 2009)

[chuck44l]

2.) Summary of Entest’s technology


Chronic Obstructive Pulmonary Disease (COPD):


Entest’s treatment approach for COPD is based on the development of easy-toimplement
therapies involving the use of stem cells, and other cells found in the
fat tissue of the patient. By incorporating photoceutical devices currently in use
for other clinical treatments, this invention discloses methods of increasing the
rate of cell homing, retention, and growth factor production in the lung.


a. What is COPD?:


COPD is the 4th Leading Cause of Death in the United States. Chronic
obstructive pulmonary disease (COPD) is comprised primarily of two related
diseases - chronic bronchitis and emphysema. In both diseases, there is chronic obstruction of the flow of air through the airways and out of the lungs, and the
obstruction generally is permanent and progressive over time.


b. What treatment is currently being used for COPD?


The goals of COPD treatment are:
i.) prevent further deterioration in lung function,
ii.) alleviate symptoms,
iii.) improve performance of daily activities (quality of life)
iv.) Current treatment includes:
• quitting cigarette smoking
• taking medications to dilate airways and decrease airway
inflammation (bronchodilators)
• vaccinating against flu influenza and pneumonia
• regular oxygen supplementation
• pulmonary rehabilitation.


v.) List of common medications used in treating COPD:

1. Bronchodilators


Patients who have COPD are often prescribed medications called
bronchodilators. Bronchodilators work by relaxing and expanding the
smooth muscle of the airways, making it easier to breath. Three types
of bronchodilators are commonly used for treatment of COPD. Which
bronchodilator will work best for you?


2. Glucocorticoids


If you have COPD, your doctor may have prescribed glucocorticoids,
or steroids, as part of your COPD treatment plan. While glucocorticoids
have many benefits, they also have serious risks and side effects. Are
you aware of the risks and benefits associated with the use of
glucocorticoids?


3. Antibiotics

People with COPD are more prone to bacterial lung infections than
most. And, if you have a bacterial lung infection, then chances are your
doctor will have prescribed you an antibiotic. Learn more about
antibiotic therapy and how your doctor tells the difference between a
simple virus and a bacterial lung infection.


4. Oxygen Therapy


Has your doctor recently prescribed oxygen therapy as part of your
COPD treatment plan? If so, you may be wondering why you need it,
and more importantly, how you should use it. Learn the benefits of
oxygen therapy if you have COPD and how to use your oxygen safely.


5. Flu Vaccine


Flu shots not only help prevent the flu, they can help COPD patients
fight off potential exacerbations of symptoms, which are periods of time
when your COPD may worsen. Learn how flu shots can help prevent
COPD exacerbation.


6. Pneumonia Vaccine


People with COPD are at greater risk for developing pneumococcal
pneumonia, a serious lung infection that kills 1 out of every 20 people
who get it. And, even if you have already had a pneumonia vaccine,
the Centers for Disease Control recommend that certain high-risk
groups have a second dose. Are you among the high-risk group?

[chuck44l]

3.) Intellectual Property and Patents


Currently, Entest has two patent applications filed covering Chronic Obstructive
Pulmonary Disease Treatment using adult stem cells derived from adipose tissue with
photoceutical device enhanced targeting for regeneration of damaged lung tissue. The
Company has recently filed a patent application relating to cancer (“Cancer therapy by
intratumoral injection of a chemotherapeutic agent in combination with a bioactive
immunostimulatory agent). The Company has also filed a patent application covering
Traumatic Brain Injury Adult Stem Cell Therapy. Additionally, the Company has 192
disposable instruments used in stem cell harvesting covered by seven patent
applications.


4.) Revenue Model for Entest BioMedical Inc.


Entest BioMedical, Inc.’s first tier revenue sources should generate from its Immunotherapeutic
cancer vaccine for use in canines (dogs). This patent pending treatment involves perfecting the use of cell lines for sustained release of immunologically relevant cytokines for maximum anti-tumor immune responses in treating cancer. The treatment process itself will utilize an implantable encapsulation device as the vaccine delivery system and the initial focus will be treatment of cancer in canines. The Company’s initial first year goal is to treat 2,000 dogs at $3,000 per dog (yielding $6,000,000 in revenue) and believes revenue could begin within six to nine months. This canine cancer treatment may also provide clinical support for expansion into human cancer treatment.


Entest has applied for a contract with the National Cancer Institute (NCI) for the initial
development of an immuno-therapeutic cancer drug. This contract, if awarded to Entest,
will have a value of $200,000 and will cover a nine month period for Phase I clinical
evaluation. If the drug demonstrates reasonable efficacy, NCI may coordinate and fund
further development through Phases II and III, with the ultimate goal being
commercialization of the drug in partnership with NCI.


There is currently no cure for Chronic Obstructive Pulmonary Disease (COPD) and
therapy is limited to management of the condition and its symptoms. Over the next 5
years, it is estimated that over $170 billion will be spent on treating COPD in the United
States. Entest believes its COPD treatment, which utilizes patent pending adult stem
cell therapy coupled with photoceutical device enhancement, has the potential to
reverse COPD related lung damage as well as alleviate symptoms. The Company
foresees substantial revenue in treating COPD and is currently in discussions with
several entities regarding possible joint ventures involving the Company’s developing
patent pending treatment.


Entest anticipates funding a significant amount of its research development costs by
obtaining grant funding. The Company is in the process of applying for $3 million of
federal grant funding for both COPD treatment and immuno-therapeutic treatment of cancer.


KEY PERSONNEL



Meet the Entest BioMedical Management Team

David R. Koos, PhD, DBA - Chairman and CEO, Secretary, Acting CFO
Dr. Koos has been involved with investment banking, venture capital, and investor relations for more than 20 years. He is currently Chairman, CEO, and acting CFO of Bio-Matrix Scientific Group, Inc. He has worked with major Wall Street investment banks and was a Vice-President of Investments with Sutro & Co., Everen Securities, and Dean Witter. In addition, Dr. Koos holds a Ph.D. degree in Economic Sociology, a DBA in Corporate Finance, both from Atlantic International University. In addition, Dr. Koos holds M.A. degree in Economic Sociology from the University of California, Riverside, California.

Feng Lin, MD, PhD – Director of Research

Dr. Feng Lin has a strong background in drug/DNA in vivo delivery, oncology and tumor immunotherapy, cell and molecular biology, and animal model work. He also has extensive experience with tissue imaging, and stem cell differentiation. Previously, Dr. Lin was a Senior Research Scientist, Research & Development with Inovio BC, San Diego and Postdoctoral Fellow in the Burnham Institute for Medical Research, La Jolla. He received his M.D. from Central South University Xiangya School of Medicine, Changsha, China, along with a M.S. Biochemistry & Molecular Biology and a Ph.D. Hematology & Physiology from the same institution. Dr. Lin's research work has been widely published in international scientific journals.

Marilyn Panahi – Director of Quality Assurance

MS. Panahi brings more than 15 years experience in the implementation and management of the EPA's Good Laboratory Practice Standards (GLPS) Compliance Monitoring Program and the FDA's Good Manufacturing Practices (GMP)/Quality Systems Regulation.Previously, Ms. Panahi was Quality Manager, Therapheresis, Inc., San Diego. Ms. Panahi is a graduate of San Diego State University with a B.S. in Microbiology. Ms. Panahi also holds a Certificate in Science of Regulatory Affairs for the Drug and Biologic Industry and a Certificate in Quality Assurance/Control for the Drug and Biologic Industry, both from the University of California at San Diego.

Corinne Knutson — Director of Grant Development

Ms. Knutson has more than five years of experience writing grant proposals and reports for nonprofit organizations and small business concerns involved in cutting-edge research and development. Knutson has a Bachelors Degree in Journalism from the University of Hawaii and a Certificate in Grant Management & Administration from California State University. Previous grant writing experience encompasses drafting and submitting grant proposals and reports for clients seeking funding from organizations including the Tiffany & Co. Foundation, National Oceanic and Atmospheric Administration (NOAA), National Fish and Wildlife Foundation (NFWF), the David & Lucile Packard Foundation, and the John D. and Catherine T. MacArthur Foundation. Currently, Ms. Knutson is assisting Entest BioMedical in securing grant funding from various governmental agencies, foundations and other organizations to develop its research projects and move towards commercialization of products.

Dessimira Ivanova – Director of Project Development

Ms. Ivanova has been involved with project development for the past six years, specializing in biotechnology related R & D projects. She has worked with faculty and technology transfer licensing officers at various institutions including the University of California – San Diego. In addition to her experience in coordinating research and development programs, Ms. Ivanova has an MBA from San Diego State University where she specialized in International Business. Currently, she is assisting Entest BioMedical in developing its research model for Chronic Obstructive Pulmonary Disease (COPD). Her activities in this project include business plan and budget development, scientific expert sourcing and facilities management.

Corporate Headquarters
Entest BioMedical Inc.
8885 Rehco Road
San Diego, California 92122
U.S.A.
Telephone:
Fax: (619)325-0702
Email: info@EntestBio.cominfo@EntestBio.comThis e-mail address is being protected from spambots. You need JavaScript enabled to view it

[chuck44l]

[chuck44l]

SAN DIEGO, CA--(Marketwire - 03/15/10) - Entest BioMedical Inc. (OTC.BB:ENTB - News) announced today It is creating a bioinformatics-based program combining advances in molecular knowledge of Chronic Obstructive Pulmonary Disease (COPD) with computer-powered search tools to integrate existing and newly generated data for this condition. Bioinformatics is defined as the collection, classification, storage, and analysis of biochemical and biological information using computers especially as applied in molecular genetics and genomics. One of the best known applications of bioinformatics methods is the Human Genome Project.

"While there are many pieces to the puzzle of COPD, the majority of research today is focused on finding new pieces as opposed to making sense of the pieces we already have," said Dr. Feng Lin, Scientific Director of Entest. "We have begun a Program based on using various automated algorithms to mine existing data sets and develop hypotheses that can be experimentally tested."

One of the initial tasks of the program is the creation of databases containing all genes associated with various aspects of COPD. These genes will then categorized based on biological functionality and association with each other. Once a global perspective of the genes and how their functions inter-relate is achieved, examination can be made as to which existing drugs may act somewhere on the pathway and possibility induce a benefit.

"By assembling everything known in the literature regarding COPD at a molecular level, our scientists will have an overall understanding of this terrible disease," said David Koos. "In addition, the bioinformatics approach will allow Entest to develop new intellectual property, some of which we anticipate will include new uses of existing drugs on the market."

The basis for the current program originates from internal Entest discussions involving the need for appropriate biomarkers for planned photoceutical trials. Given that the mechanism of action of photoceuticals is still relatively unclear, clinical trials will require sensitive biomarkers, which to some extent are not available in COPD. It is anticipated that the bioinformatics program will be of benefit in this aspect.

The Company will be hosting another interview with Its Chairman & CEO on Wednesday morning at 11 a.m. PDT at www.Entestbioblog.com/live. Mr. Koos will discuss the importance of this new bioinformatics approach on strengthening Its COPD treatment model.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTC.BB:ENTB - News) is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). ENT - 576™ is a proprietary laser device currently under development by Entest. The Company has filed 3 patent applications relating to the treatment of COPD. Entest Biomedical, Inc. is a majority owned subsidiary of Bio-Matrix Scientific Group Inc. (OTC.BB:BMSN - News). Recently Entest published in the peer reviewed literature its platform technology, which is available at http://www.translational-medicine.co...-5876-8-16.pdf

About Bio-Matrix Scientific Group:

Bio-Matrix Scientific Group Inc. (OTC.BB:BMSN - News) is a biotechnology company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories. David Koos serves as Chairman & CEO concurrently for BMSN and ENTB.

Forward-looking statements:

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

[chuck44l]

ENTB 1.69"s printing we alerted this one at 1.30 Heads up here folks!!!!

[chuck44l]

Don't forget The Company will be hosting another interview with Its Chairman & CEO on Wednesday morning at 11 a.m. PDT at www.Entestbioblog.com/live. Mr. Koos will discuss the importance of this new bioinformatics approach on strengthening Its COPD treatment model.